TheraRadar
← Back
Data updated: Mar 29, 2026

HEBEI CHANGSHAN

CardiovascularRespiratory
Generics

HEBEI CHANGSHAN is a generic drug manufacturer focused on Cardiovascular, Respiratory.

2026
Since
1
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2026-01-07
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2025-11-25
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2024-06-26
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2024-06-26
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2024-06-14
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 50%
1 drugs
Respiratory 50%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular, Respiratory
AstraZeneca big-pharma
Respiratory, Cardiovascular
Boehringer Ingelheim big-pharma
Respiratory, Cardiovascular
GE HEALTHCARE specialty
Cardiovascular, Respiratory
BRACCO specialty
Cardiovascular, Respiratory